621 studies (2 from unattributed sources) on Semaglutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Polaris Peptides | 26 | 99.51% | View COA → |
| Qingdao Sigma Chemical | 22 | 99.52% | View COA → |
| Peptide Sciences | 21 | 99.71% | View COA → |
| Nexaph | 18 | 98.41% | View COA → |
| Peptide Crafters | 16 | 99.8% | View COA → |
| (unknown) | 16 | 99.57% | View COA → |
| Aminos Research | 15 | 99.73% | View COA → |
| Nuscience Peptides | 14 | 99.02% | View COA → |
Recent certificates: #22090 (99.8%) · #22091 (99.7%) · #14540 (99.9%) · #13228 (99.458%) · #13229 (99.653%) · #13477 (99.9%)
Manufacturers with published third-party certificates of analysis for Semaglutide. Open a vendor to see every batch we've verified.
A clinical study is underway to assess how CagriSema, cagrilintide, and semaglutide impact muscle health in overweight individuals with prediabetes during weight loss.
The outcome of this trial could significantly impact the treatment landscape for Type 2 Diabetes. If flexible-dose oral semaglutide demonstrates superior efficacy or a comparable safety profile to sitagliptin, it coul…
Observational study explores if personality attributes and behavioral AI can predict patient adherence and weight loss success during a semaglutide program in the Latino community.
Semaglutide trial will assess its impact on circulating vessel-repairing cells over 6 months in patients with type 2 diabetes or obesity.
If this trial demonstrates a protective effect, it would represent a significant paradigm shift in managing diabetic eye disease. Semaglutide could become a crucial therapeutic option not just for glycemic control, bu…
This preclinical study highlights the promising potential of Cissus quadrangularis and Dichrostachys glomerata extracts as natural agents for obesity and metabolic health management. For biohackers and individuals exp…
Understanding the real-world benefits of switching from DPP-4i to oral semaglutide is critical for clinicians and patients managing T2DM. This study will provide valuable insights into how oral semaglutide performs in…
This projection analysis provides crucial insights for clinicians and policymakers regarding the real-world impact of oral semaglutide in managing type 2 diabetes with high cardiovascular risk. Integrating oral semagl…
This review significantly expands the understanding of GLP-1 RAs beyond diabetes and obesity, establishing their utility in heart failure management, particularly for HFpEF/HFmrEF. For clinicians and biohackers, this …
Dulaglutide reduced stroke risk by 23% (RR: 0.77) and semaglutide lowered cardiovascular mortality by 26% (RR: 0.74) in T2DM patients, a network meta-analysis of 67,769 found.
This study suggests that semaglutide could become a valuable adjunctive neuroprotective therapy for patients experiencing acute large vessel occlusion stroke, particularly those ineligible for or not receiving intrave…
Phase 1 trial to compare Cagrilintide B (with placebo semaglutide I) and Cagrilintide D blood levels in 234 adults with overweight or obesity over 17 weeks.
A higher-dose oral semaglutide could significantly impact obesity and overweight management by offering a potent, non-injectable alternative to existing therapies. Oral semaglutide 25 mg could provide enhanced conveni…
This trial directly confronts a significant challenge in GLP-1 therapy: mitigating the loss of lean muscle and bone mass during substantial weight reduction. If successful, the findings could establish a new, integrat…
This completed Phase II study for BI 456906 is a crucial step in developing new treatments for Type 2 Diabetes Mellitus and obesity. If positive, the findings could identify optimal dosing strategies for a novel compo…
If successful, this trial could establish semaglutide as a crucial adjunct therapy for individuals with Double Diabetes, potentially improving glycemic control beyond insulin alone and reducing overall insulin require…
A completed Phase 3 trial (NCT04074161) compared semaglutide 2.4 mg weekly to liraglutide 3.0 mg daily for weight management in overweight/obese adults over 68 weeks.
Real-world data confirm semaglutide's efficacy for obesity when adherence is maintained, mirroring clinical trial results for persistent users. This study provides crucial insights for healthcare providers and payers,…
Clarifying the link between semaglutide and NAION is critical for patient counseling and prescribing practices. If a significant association is confirmed, it could lead to updated guidelines for monitoring ocular heal…
This review provides crucial insights for peptide users and clinicians, clarifying why dual GLP-1R/GIPR agonists like tirzepatide offer superior weight loss and metabolic improvements over single GLP-1RAs like semaglu…
This study introduces a powerful SPRM methodology for characterizing peptide-receptor interactions directly on live cells, offering a significant advancement over traditional methods. This label-free, real-time approa…
This review highlights the critical need for individualized perioperative management protocols for patients on GLP-1RAs. Clinicians should avoid routine discontinuation of GLP-1RAs before surgery, instead focusing on …
Two phase 3, randomized, placebo-controlled trials (evoke and evoke+) investigated oral semaglutide 14 mg for efficacy and safety in early-stage symptomatic Alzheimer's disease.
Authors of the SOUL trial address a comment regarding the impact of oral semaglutide on kidney outcomes in people with type 2 diabetes.
This protocol outlines a crucial step towards potentially repurposing semaglutide for cocaine use disorder (CUD), a condition with no FDA-approved pharmacotherapies. If successful, this trial could establish a novel, …
Oral semaglutide 25 mg achieved exposure similar to SC 2.4 mg and led to greater weight loss in simulated studies, according to a meta-analysis.
Semaglutide offers a viable pathway for severely obese ESHF patients to become eligible for life-saving heart transplantation, potentially expanding access to this critical procedure. For clinicians, this suggests int…
This analysis highlights a critical shift in the clinical research paradigm for GLP-1 agonists in obesity, moving beyond primary weight loss to encompass a wider spectrum of metabolic and organ-specific benefits. Clin…
This research offers a crucial shift in the narrative around GLP-1RA discontinuation, suggesting that weight regain is not an inevitable outcome for all patients. For individuals considering or undergoing GLP-1RA ther…
This review underscores a paradigm shift in metabolic disease management, moving beyond single-target approaches to powerful multi-agonist strategies. For individuals managing T2DM, obesity, or MASLD, the emergence of…
This review highlights a critical distinction for peptide users and clinicians: only GLP-1R agonists currently possess reproducible, high-quality evidence for a specific musculoskeletal indication (knee osteoarthritis…
Semaglutide offers a crucial therapeutic option for PWH who frequently face co-occurring MASLD and liver fibrosis alongside high rates of cardiometabolic conditions. Given that PWH are aging and experiencing more meta…
Users of semaglutide must exercise extreme caution regarding sourcing, as counterfeit products pose significant health risks. This research underscores the critical importance of obtaining semaglutide only from legiti…
If successful, this trial could establish semaglutide as a novel neuroprotective adjunct to standard endovascular treatment for acute LVO stroke, potentially reducing long-term disability. Given semaglutide's establis…
If this pilot study successfully demonstrates feasibility and initial positive signals, Semaglutide could represent a significant advancement as an adjunct therapy for Alcohol Use Disorder (AUD) in post-bariatric surg…
Understanding the real-world kinetics and variability of Wegovy®'s effects on body composition and cardiovascular health is crucial for optimizing patient care. This study will provide valuable insights into how patie…
If successful, this trial could represent a significant breakthrough, offering the first FDA-approved pharmacotherapy for methamphetamine use disorder (MeUD). A positive outcome would provide clinicians with a much-ne…
This head-to-head Phase 3 trial is crucial for understanding the comparative efficacy and safety of Tirzepatide versus Semaglutide in Type 2 Diabetes patients already on metformin. The results will directly inform cli…
This finding suggests a novel, direct mechanism by which GLP-1RAs could offer neuroprotection in Alzheimer's disease, moving beyond their established metabolic benefits. For individuals interested in neurodegenerative…
A matched cohort study directly compared sleeve gastrectomy to semaglutide (2.4 mg/week) plus intensive lifestyle modifications for obesity management.
If semaglutide is found to significantly improve coronary flow reserve in both diabetic and non-diabetic patients, it would further solidify its role in cardiovascular protection, extending beyond its established bene…
This Phase 1 trial represents a significant step towards identifying novel adjunctive therapies for Type 1 Diabetes, moving beyond insulin-only regimens. If NNC0194-0499 proves safe and demonstrates promising prelimin…
Shared decision-making between patients and their care teams is warranted when considering the initiation, continuation, or discontinuation of GLP-1 RAs in light of the potential, albeit low and inconsistent, risk of …
While specific results are not yet published, a successful demonstration of bioequivalence between these two semaglutide formulations would have significant practical implications. It would confirm that patients can e…
If positive, this research could significantly impact Type 1 Diabetes management, offering a novel adjunctive strategy to improve glycemic control and potentially mitigate common issues like weight gain or post-meal s…
A Phase 3 randomized trial evaluated the effect and safety of semaglutide 2.4 mg once-weekly for 68 weeks in 1961 adults with overweight or obesity.
This preclinical finding highlights a potential consideration for individuals on long-term semaglutide therapy, especially those with pre-existing chronic kidney disease or other conditions affecting bone health. Mild…
Understanding the pharmacokinetic equivalence of different delivery devices for semaglutide is critical for both clinicians and patients. Consistent drug exposure ensures predictable therapeutic effects, which is vita…
Optimizing CagriSema dosing could expand treatment options for obesity by identifying regimens that balance efficacy with improved tolerability, potentially leading to broader patient adoption and adherence. Finding e…
A randomized trial will compare semaglutide, tirzepatide, and metformin in 66 obese adults to assess their impact on genetic aging over 24 weeks.
Free, no account — handy when you're working with Semaglutide.